Impact of Phosphodiesterase-5 Inhibitor Treatment Delay on Secondary Raynaud’s Phenomenon Outcomes

This dataset includes information collected from patient with secondary Raynaud's phenomenon treated with phosphodiesterase-5 inhibitors. Demographic infromation, secondary Raynaud's phenomenon characteristics, and phosphodiesterase-5 inhibitor effects determined by physician and/or patient reports were collected. Multivariate logistic regression assessed associations with adverse outcomes using RStudio (α=0.05).